Peptide Super-Agonist Enhances T-Cell Responses to Melanoma.
CD8-Positive T-Lymphocytes
/ immunology
Cancer Vaccines
/ immunology
Cell Line, Tumor
HLA-A2 Antigen
/ immunology
Humans
Immunotherapy, Adoptive
/ methods
Lymphocytes, Tumor-Infiltrating
/ immunology
Melanoma
/ immunology
Peptides
/ immunology
Receptors, Antigen, T-Cell
/ immunology
Receptors, Antigen, T-Cell, alpha-beta
/ immunology
T-Lymphocytes, Cytotoxic
/ immunology
T-cell receptor
altered peptide ligand
cancer immunotherapy
cancer vaccine
melanoma
tumour infiltrating lymphocyte
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
06
2018
accepted:
06
02
2019
entrez:
2
4
2019
pubmed:
2
4
2019
medline:
27
5
2020
Statut:
epublish
Résumé
Recent immunotherapeutic approaches using adoptive cell therapy, or checkpoint blockade, have demonstrated the powerful anti-cancer potential of CD8 cytotoxic T-lymphocytes (CTL). While these approaches have shown great promise, they are only effective in some patients with some cancers. The potential power, and relative ease, of therapeutic vaccination against tumour associated antigens (TAA) present in different cancers has been a long sought-after approach for harnessing the discriminating sensitivity of CTL to treat cancer and has seen recent renewed interest following cancer vaccination successes using unique tumour neoantigens. Unfortunately, results with TAA-targeted "universal" cancer vaccines (UCV) have been largely disappointing. Infectious disease models have demonstrated that T-cell clonotypes that recognise the same antigen should not be viewed as being equally effective. Extrapolation of this notion to UCV would suggest that the
Identifiants
pubmed: 30930889
doi: 10.3389/fimmu.2019.00319
pmc: PMC6425991
doi:
Substances chimiques
Cancer Vaccines
0
HLA-A2 Antigen
0
Peptides
0
Receptors, Antigen, T-Cell
0
Receptors, Antigen, T-Cell, alpha-beta
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
319Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Références
Eur J Immunol. 2001 Jan;31(1):156-65
pubmed: 11169449
Cancer Res. 2001 Jul 1;61(13):5153-60
pubmed: 11431354
Eur J Immunol. 2002 Nov;32(11):3181-90
pubmed: 12555663
Clin Cancer Res. 2003 Feb;9(2):669-77
pubmed: 12576434
J Immunol. 2003 May 15;170(10):5103-9
pubmed: 12734356
Eur J Immunol. 2003 Nov;33(11):3175-85
pubmed: 14579286
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
pubmed: 15299374
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Nature. 1991 Nov 7;354(6348):84-6
pubmed: 1719428
J Immunol. 2007 May 1;178(9):5727-34
pubmed: 17442956
J Immunother. 2007 Feb-Mar;30(2):234-9
pubmed: 17471170
J Biol Chem. 2007 Aug 17;282(33):23799-810
pubmed: 17540778
J Immunol. 2008 Feb 1;180(3):1526-34
pubmed: 18209048
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3849-54
pubmed: 18319339
J Immunol Methods. 2009 Jan 1;340(1):11-24
pubmed: 18929568
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
J Biol Chem. 2009 Oct 2;284(40):27281-9
pubmed: 19605354
J Immunol. 2009 Oct 15;183(8):5397-406
pubmed: 19786555
J Immunol. 2010 Aug 15;185(4):2600-10
pubmed: 20639478
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
N Engl J Med. 2011 Aug 25;365(8):725-33
pubmed: 21830940
J Biol Chem. 2012 Jan 6;287(2):1168-77
pubmed: 22102287
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Cold Spring Harb Perspect Biol. 2012 Jun 01;4(6):null
pubmed: 22661634
Nat Rev Immunol. 2012 Sep;12(9):669-77
pubmed: 22918468
Eur J Immunol. 2012 Dec;42(12):3174-9
pubmed: 22949370
J Biol Chem. 2012 Oct 26;287(44):37269-81
pubmed: 22952231
Blood. 2013 Feb 14;121(7):1112-23
pubmed: 23255554
N Engl J Med. 2013 Apr 18;368(16):1509-1518
pubmed: 23527958
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1260-73
pubmed: 23793152
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
Clin Exp Immunol. 2014 Jul;177(1):47-63
pubmed: 24673376
J Immunol. 2015 Jan 1;194(1):463-74
pubmed: 25452566
Eur J Immunol. 2015 Feb;45(2):584-91
pubmed: 25471691
Clin Exp Immunol. 2015 May;180(2):255-70
pubmed: 25496365
N Engl J Med. 2015 Feb 19;372(8):711-23
pubmed: 25693011
Immunology. 2015 Sep;146(1):11-22
pubmed: 26076649
J Immunol Methods. 2016 Mar;430:43-50
pubmed: 26826277
Immunol Cell Biol. 2016 Jul;94(6):573-82
pubmed: 26846725
Clin Cancer Res. 2016 Aug 1;22(15):3734-45
pubmed: 27006492
J Clin Invest. 2016 Jun 1;126(6):2191-204
pubmed: 27183389
Clin Exp Immunol. 2017 Jan;187(1):124-137
pubmed: 27324616
J Immunother Cancer. 2016 Sep 20;4:53
pubmed: 27660707
Cancer Immunol Immunother. 2017 Jun;66(6):683-695
pubmed: 28238174
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Clin Cancer Res. 2017 Oct 1;23(19):5779-5788
pubmed: 28679768
J Immunol. 2018 Apr 1;200(7):2263-2279
pubmed: 29483360
J Clin Invest. 2018 Apr 2;128(4):1569-1580
pubmed: 29528337
Ann Oncol. 2018 Jul 1;29(7):1575-1581
pubmed: 29688262
Front Immunol. 2018 Jun 29;9:1378
pubmed: 30008714
Hum Immunol. 1995 May;43(1):1-12
pubmed: 7558923
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4102-7
pubmed: 8633023
Cancer Res. 1997 Oct 15;57(20):4570-7
pubmed: 9377571
J Immunol. 1998 Feb 15;160(4):1750-8
pubmed: 9469433